Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

CD34+CD38−CD58− cells are leukemia-propagating cells in Philadelphia chromosome-positive acute lymphoblastic leukemia

Leukemia volume 28, pages 2398–2401 (2014)Cite this article

Subjects

Prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) has improved with the use of tyrosine kinase inhibitors but most persons relapse. Some persons with Ph+ALL develop resistance to tyrosine kinase inhibitors but others relapse because of the persistence of quiescent leukemia stem cells (also termed leukemia-propagating cells (LPCs)).

LPCs are defined by their ability to initiate human leukemia and to proliferate and self-renew in immune-deficient mice.1, 2, 3, 4 LPCs in persons with acute myeloid leukemia have diverse phenotypes but most are CD34+CD38−.1,4 Recently, persons with acute myeloid leukemia and high LPCs frequencies in the bone marrow and persons whose bone marrow cells have a gene expression profile typical of LPCs are reported to have worse clinical outcomes following therapy with anti-leukemia drugs.5,6

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Bonnet D, Dick JE Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–737.

    Article  CAS  Google Scholar 

  2. Cobaleda C, Sanchez-Garcia I B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. Bioessays 2009; 31: 600–609.

    Article  Google Scholar 

  3. Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008; 22: 1207–1213.

    Article  CAS  Google Scholar 

  4. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645–648.

    Article  CAS  Google Scholar 

  5. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086–1093.

    Article  CAS  Google Scholar 

  6. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA . Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010; 304: 2706–2715.

    Article  CAS  Google Scholar 

  7. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, Flores T, Garcia-Sanz R, Gonzalez M et al. A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood 2000; 95: 1007–1013.

    CAS  PubMed  Google Scholar 

  8. Chen JS, Coustan-Smith E, Suzuki T, Neale GA, Mihara K, Pui CH et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001; 97: 2115–2120.

    Article  CAS  Google Scholar 

  9. Archimbaud E, Thomas X, Campos L, Magaud JP, Dore JF, Fiere D Expression of surface adhesion molecules CD54 (ICAM-1) and CD58 (LFA-3) in adult acute leukemia: relationship with initial characteristics and prognosis. Leukemia 1992; 6: 265–271.

    CAS  PubMed  Google Scholar 

  10. Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012; 119: 5584–5590.

    Article  CAS  Google Scholar 

  11. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119: 3256–3262.

    Article  CAS  Google Scholar 

  12. Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009; 15: 4777–4783.

    Article  Google Scholar 

  13. Mazurier F, Doedens M, Gan OI, Dick JE Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med 2003; 9: 959–963.

    Article  CAS  Google Scholar 

  14. Tanaka T, Tsudo M, Karasuyama H, Kitamura F, Kono T, Hatakeyama M et al. A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells. J Immunol 1991; 147: 2222–2228.

    CAS  PubMed  Google Scholar 

  15. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315–1321.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Professor Robert Peter Gale kindly reviewed the typescript. The work was supported by the National Natural Science Foundation of China (81370638 and 81230013), the National Clinical Priority Specialty, the Beijing Municipal Science and Technology Program (grant no. Z141100000214011), and Peking University People’s Hospital Research and Development Funds (RDB2012-23).

Author information

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

    Y Kong, Y-J Chang, Y-R Liu, Y-Z Wang, Q Jiang, H Jiang, Y-Z Qin, Y Hu, Y-Y Lai & X-J Huang

  2. Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China

    Y Hu & X-J Huang

  3. Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    C-W Duan & D-L Hong

Authors
  1. Y Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y-J Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y-R Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y-Z Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Q Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y-Z Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y-Y Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C-W Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D-L Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. X-J Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X-J Huang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kong, Y., Chang, YJ., Liu, YR. et al. CD34+CD38−CD58− cells are leukemia-propagating cells in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 28, 2398–2401 (2014). https://doi.org/10.1038/leu.2014.228

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.228

This article is cited by

Search

Advanced search

Quick links